G60511.mp4 Apr 2026

Indicated for maintaining open airways in patients with tracheobronchial strictures caused by malignant neoplasms.

The iCARUS clinical trial demonstrated a 96.4% primary patency rate at 9 months, showing the device is highly effective for vascular treatment. g60511.mp4

According to the official Instructions for Use (IFU) , medical professionals should note: Indicated for maintaining open airways in patients with

may occur if used in patients with active inflammation or infections. g60511.mp4